Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

Author: Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Publisher: Springer Publishing Company

ISSN: 0167-6806

Source: Breast Cancer Research and Treatment, Vol.125, Iss.3, 2011-02, pp. : 775-784

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content